BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
And there are several trials that are ongoing right now asking that question in the perioperative setting. And similar to what we saw with the cisplatinum plus checkpoint inhibitor trials, they have a neoadjuvant component and an adjuvant component.
0
💬
0
Comments
Log in to comment.
There are no comments yet.